Distillate Capital Partners’s AbbVie ABBV Stock Holding History

Distillate Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$56.6M	Buy	260,373 +40,685	+19%	+$9.02M	2.98%	1
2025 Q4	$50.2M	Sell	219,688 -6,633	-3%	-$1.51M	2.58%	1
2025 Q3	$52.4M	Sell	226,321 -2,875	-1%	-$585K	2.72%	1
2025 Q2	$42.5M	Sell	229,196 -24,397	-10%	-$4.53M	2.28%	4
2025 Q1	$53.1M	Sell	253,593 -61,009	-19%	-$11.9M	2.72%	3
2024 Q4	$55.9M	Buy	314,602 +26,804	+9%	+$4.93M	2.75%	2
2024 Q3	$56.8M	Sell	287,798 -3,716	-1%	-$694K	2.85%	8
2024 Q2	$50M	Buy	291,514 +291,434	+364,293%	+$48.3M	2.65%	3
2024 Q1	$14.6K	Hold	80	–	–	2.45%	19
2023 Q4	$12.4K	Hold	80	–	–	2.7%	25
2023 Q3	$11.9K	Buy	80 +10	+14%	+$1.47K	3.01%	27
2023 Q2	$9.43K	Hold	70	–	–	3.05%	25
2023 Q1	$11.2K	Sell	70 -1	-1%	-$153	2.86%	23
2022 Q4	$11.5K	Sell	71 -106,346	-100%	-$16.3M	1.06%	28
2022 Q3	$15.4M	Sell	106,417 -8,915	-8%	-$1.28M	2.06%	4
2022 Q2	$17.7M	Sell	115,332 -9,417	-8%	-$1.44M	2.52%	3
2022 Q1	$20.2M	Sell	124,749 -2,039	-2%	-$296K	2.88%	1
2021 Q4	$17.2M	Buy	126,788 +43,903	+53%	+$5.19M	2.88%	1
2021 Q3	$8.94M	Buy	82,885 +13,733	+20%	+$1.57M	2.38%	2
2021 Q2	$7.79M	Buy	+69,152	New	+$7.79M	2.17%	4

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Distillate Capital Partners's ABBV Position: Q1 2026 in Review

Distillate Capital Partners increased its AbbVie (ABBV) stake by 19% in Q1 2026, buying an estimated $9.02M and bringing the position to 260,373 shares worth $56.6M. The position accounts for 2.98% of the portfolio, ranked #1.

Distillate Capital Partners first reported a position in ABBV in Q2 2021 and has held it in 20 quarters since. The position peaked at $56.8M in Q3 2024. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Distillate Capital Partners held 260,373 shares of AbbVie worth $56.6M as of Q1 2026.
Distillate Capital Partners bought 40,685 AbbVie shares in Q1 2026, an estimated $9.02M.
AbbVie made up 2.98% of Distillate Capital Partners's portfolio in Q1 2026, its #1 holding.
Distillate Capital Partners first reported a position in AbbVie in Q2 2021 and has held it in 20 quarters since.
Distillate Capital Partners's AbbVie position peaked at $56.8M in Q3 2024.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Distillate Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.